Tianjin Development Holdings (DE:TJN) has released an update.
Tianjin Development Holdings’ subsidiary, Lisheng Pharmaceutical, has entered into a new wealth management agreement with CBHB, subscribing to a structured deposit of RMB210 million. The deposit, with a term from September 30, 2024, to February 7, 2025, offers an annualized return rate between 1.5% and 2.5%. This transaction is classified as discloseable under the Listing Rules, with all applicable percentage ratios below 25%.
For further insights into DE:TJN stock, check out TipRanks’ Stock Analysis page.